Ornim Inc.
Monitoring vital organs using light and ultrasound
This article was originally published in Start Up
Executive Summary
By combining near-infrared spectroscopy with ultrasound waves, clinicians now have the ability to noninvasively monitor blood flow changes and oxygen saturation in the brain. The CerOx monitor, from Israel-based Ornim Inc., is a vital organ monitoring device that can simultaneously monitor the brain and other tissue of critical care patients. The company estimates that there are approximately 10 million medical procedures annually that could benefit from CerOx, ranging from patients with traumatic brain injury to occlusive vascular disease.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.